91252-54-9Relevant articles and documents
BTK INHIBITORS
-
Page/Page column 229, (2022/02/15)
Provided are compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R7, R8, R9, A1, A2, Q1, Q2, Q3, A, Z, m and n are as defined herein; pharmaceutical compositions comprising said compounds or pharmaceutically acceptable salts thereof, and pharmaceutically acceptable excipients; and methods of treating a disorder responsive to inhibition of Bruton's tyrosine kinase using said compounds, or pharmaceutically acceptable salts thereof, or said pharmaceutical compositions.
Development of a continuous flow photoisomerization reaction converting isoxazoles into diverse oxazole products
Bracken, Cormac,Baumann, Marcus
, p. 2607 - 2617 (2020/03/11)
A continuous flow process is presented, which directly converts isoxazoles into their oxazole counterparts via a photochemical transposition reaction. This results in the first reported exploitation of this transformation to establish its scope and synthe
Efficient synthesis of ESI-09, a novel non-cyclic nucleotide EPAC antagonist
Chen, Haijun,Ding, Chunyong,Wild, Christopher,Liu, Huiling,Wang, Tianzhi,White, Mark A.,Cheng, Xiaodong,Zhou, Jia
, p. 1546 - 1549 (2013/03/14)
A concise and efficient synthetic approach to producing a novel non-cyclic nucleotide EPAC antagonist ESI-09 and its new analogs is reported. Key features of the synthesis include a mild and reliable one-pot procedure for an isoxazole synthon, as well as a modified one-pot protocol for the cyanomethyl ketone key intermediate. The synthesis requires inexpensive starting materials and only three linear steps for the completion in a total yield of 53%.
